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& Federico Rojo*,‡ ,9
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Triple-negative breast cancer (TNBC) is more aggressive than other breast cancer subtypes. TNBC is charac-
terized by increased expression of Programmed Death-ligand 1 (PD-L1), a signal used by many tumors to
escape the immune response. Expression of PD-L1 is a positive predictor of response to immunotherapy;
therefore, it should be investigated in TNBC in order to select patients who may benefit from anti-PD-L1
therapies. While many PD-L1 assays are available, only the VENTANA platform with the anti-PD-L1 (SP142)
antibody is licensed as a companion diagnostic device for selecting patients with metastatic/advanced
TNBC who are candidates for treatment with atezolizumab. In this article, we provide a summary of an
expert round-table discussion about PD-L1 testing, using the SP142 antibody in metastatic TNBC.
Lay abstract: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. Recent
discoveries in TNBC have shown that the higher the expression of the surface molecule PD-L1 in the cancer
cells, the better the response of patients to immunotherapy. While several tests or diagnostics assays for
detecting PD-L1 exist, only the antibody anti-PD-L1 SP142 possesses proven diagnostic value for selecting
metastatic TNBC patients eligible for atezolizumab immunotherapy. Throughout the present article, a
group of experts discusses how to best carry out the assessment of PD-L1 status with this assay.
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Advances in our knowledge of the oncogenesis of breast cancer and the need to improve prognosis have led to the
development of new treatments to target molecules involved in the growth and proliferation of tumor cells (TCs).
However, in recent years, new immunotherapies have been designed to treat breast tumors [1].
Many TCs can escape the immune system using various mechanisms, such as mutation or loss of tumor-specific
antigens, loss of MHC class I protein expression, defects in antigen processing and presentation pathways, T-cell
receptor signaling and costimulation, upregulation of inhibitory immune checkpoint pathways by TCs and/or
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Special Report Peg, López-Garcı́a, Comerma et al.
immune cells (ICs) within the tumor microenvironment, namely, the PD-1 axis [2]. When PD-1 expressed on ICs
is activated by its ligands, PD-L1 or PD-L2, it attenuates lymphocyte activation and promotes the development
of functional Treg, thereby enabling inhibition of the immune response [2,3]. As many tumors use this strategy to
escape the immune system, the PD-1 signaling pathway has become an interesting therapeutic target in cancer [4].
Triple-negative breast cancer (TNBC) tends to be more aggressive than other breast cancer subtypes. In fact,
until very recently, the only available approach to date was cytotoxic chemotherapy [5–9]. However, experts in this
field are witnessing with hope recent approvals for molecularly targeted therapies: two PARP inhibitors (olaparib
and talazoparib) for germline BRCA-mutated breast cancers and two checkpoint inhibitors, in other words,
atezolizumab in combination with nab-paclitaxel for (PD-L1+) and pembrolizumab in the neoadjuvant setting for
advanced TNBC [10]. Interestingly, TNBC has proven to be more immunogenic than other breast cancer subtypes,
as evidenced by the marked presence of tumor-infiltrating lymphocytes within the tumor microenvironment [10,11]
and overexpression of PD-L1 mRNA [12]. Therefore, the PD-L1/PD-1 axis has emerged as an exciting therapeutic
target in this subtype of breast cancer [13].
Upregulation of PD-L1 in locally advanced or metastatic TNBC (mTNBC) has proven to be associated with
better survival in patients treated with checkpoint inhibitors. A recent study that assessed the safety and clinical
activity of atezolizumab in TNBC showed that patients with PD-L1 expression of at least 1% tumor-infiltrating ICs
had a higher objective response rate (ORR) (12%) and longer overall survival (OS; 10.1 months) than those with
less than 1% ICs (ORR 0% and OS 6.0 months) [14]. This finding was confirmed in the Phase III IMpassion130
trial, where a clinically significant improvement in OS of 7.5 months (hazard ratio [HR]: 0.67; 95% CI: 0.53–
0.86; not formally tested due to the hierarchical study design) was observed in the PD-L1-positive population [15].
Similarly, in a Phase Ib study testing single-agent pembrolizumab in TNBC, the ORR was approximately 19% in
PD-L1-selected patients, defined by a combined positive score (CPS) of at least 1% with the 22C3 scoring system
(CPS is defined as the number of PD-L1 staining cells [TCs, lymphocytes, macrophages] divided by the total viable
TCs, multiplied by 100) [16]. Likewise, in the Phase III KEYNOTE-355 study, progression-free survival (PFS)
improved in the PD-L1-positive population (HR: 0.65; 95% CI: 0.49–0.86; p = 0.0012), although no OS data
were presented [17]. All of these results highlight the importance of assessing PD-L1 expression levels in TNBC to
select patients who will derive greater benefit from these therapies.
In this article, we present the opinion of a group of experts on how to assess PD-L1 status using SP142 in
patients with mTNBC in clinical practice.
Methods for assessing PD-L1 expression
Several PD-L1 assays are used to select patients for immunotherapy. These assays have been developed independently
for specific drugs – based on different antibody clones, staining protocols and platforms, and scoring algorithms –
and define the cut-off points for PD-L1-positive or -negative expression on TCs or on ICs [18]. Since each antibody
clone recognizes a specific epitope of PD-L1, its specific staining pattern, while similar, is not fully concordant with
the others [19–22].
The most common commercially available monoclonal PD-L1 antibodies for immunohistochemical analysis to
assess the expression of PD-L1 are the following: 22C3, 28-8, SP142, SP263 and 73-10 (Table 1) [19,23,24]. In
metastatic non-small-cell lung cancer, the 22C3 antibody clone is used as a companion assay to select patients for
pembrolizumab monotherapy, with a tumor proportion score (TPS) ≥1% being the cut-off for first-line treatment.
The 28-8 clone is used as a complementary assay for second-line treatment with nivolumab, with a TC ≥1%
cut-off. The SP142 antibody is used as a complementary assay for second-line treatment with atezolizumab, with a
cut-off of ≥1% of TCs and ≥1% of ICs. More importantly, it is classified by the US FDA as a companion diagnostic
for first-line atezolizumab monotherapy, assessed based on a TC ≥50% and IC ≥10% cut-off. Finally, the SP263
antibody can be used as a companion or complementary assay for approved immuno-oncology therapies [19,25,26].
Each antibody clone uses its own immunohistochemistry assay staining protocol. 22C3, 28-8 and 73-10 use
the DAKO Autostainer Link 48 platform (Agilent Inc., CA, USA) and SP142 and SP263 use the VENTANA
BenchMark Ultra platform (Ventana Medical Systems Inc., AZ, USA) (Table 1) [19]. The use of one or another
detection method (platform and immunohistochemistry reagents) can influence the identification of PD-L1-
positive TCs or ICs, thus indicating the significant role of the detection method, even for the PD-L1 antibody
clone [19]. Moreover, each assay has a different sensitivity for detection of PD-L1 depending on whether the test
is aimed at detecting TCs or ICs. For example, with the Lab Vision Autostainer 480S platform (Thermo Fisher
Scientific, MA, USA), SP142 stained more TCs than usual when applied as per the method sheet and, therefore,
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Table 1. Most common commercially available monoclonal PD-L1 antibodies for immunohistochemical analysis to assess
the expression of PD-L1 considering US FDA approvals for non-small-cell lung cancer.
PD-L1 antibody Drug IHC assay Cut-off Line Approval status
22C3 Pembrolizumab DAKO Autostainer Link 48 platform
(Agilent Inc)




28-8 Nivolumab DAKO Autostainer Link 48 platform
(Agilent Inc)
TC ≥1% 2L • FDA: complementary
• CE-IVD
SP142 Atezolizumab VENTANA BenchMark Ultra platform
(Ventana Medical Systems Inc)
TC ≥50% and/or IC
≥10%
1L • FDA: companion
• CE-IVD
TC ≥1 % and/or IC
≥1%
2L • FDA: complementary
• CE-IVD
SP263 Durvalumab VENTANA BenchMark Ultra platform
(Ventana Medical Systems Inc)
TC ≥1% 1L maintenance, in





Nivolumab TC ≥1% 2L • CE-IVD
Pembrolizumab TC ≥50% 1L • CE-IVD
73-10 Avelumab DAKO Autostainer Link 48 platform
(Agilent Inc)
TC ≥1 % 2L • NA
CE-IVD: European Commission in vitro diagnostic; IC: Immune cell; IHC: Immunohistochemistry; TC: Tumor cell; TPS: Tumor proportion score; NA: Not approved; 1L: First line; 2L:
Second line.
Reproduced from [24].
was more concordant with the 22C3 and 28-8 kits [19]. Thus, the staining pattern of the SP142 assay – and not
only the antibody – reveals more ICs but fewer TCs than the other PD-L1 assays.
The 22C3 and 28-8 assays, on the other hand, are highly sensitive for TCs, although their staining for ICs is
less pronounced [19]. Questions have therefore been raised about whether the tests can be used interchangeably to
inform treatment decisions for the various PD-1 and PD-L1 inhibitors.
Although the DAKO and VENTANA platforms are both used in clinical practice, a companion diagnostic label
involves a whole procedure [27]. Thus, using SP142 as a companion diagnostic for nab-paclitaxel + atezolizumab
in mTNBC involves the whole procedure based on the PD-L1 (SP142) antibody performed in the VENTANA
platform and following the protocol provided by the vendor [28]. Importantly, the FDA approval of the VENTANA
platform as a companion diagnostic for atezolizumab in TNBC was based on IMpassion130, a multicenter, inter-
national, double-blinded, placebo-controlled, randomized trial that assessed the efficacy and safety of atezolizumab
plus nab-paclitaxel in patients with unresectable, locally advanced or mTNBC [29,30].
Discussion
At the end of 2019, an expert meeting was held to discuss the various methods for assessing expression of PD-L1
in patients with mTNBC. Special emphasis was given to the VENTANA platform and the SP142 antibody clone
as the only option with proven clinical utility for the selection of patients with mTNBC who were candidates for
treatment with atezolizumab. The questions raised at the meeting are addressed below.
Given the available clinical evidence, is SP142 currently the reference diagnostic method for
assessing PD-L1 status in mTNBC?
The VENTANA PD-L1 (SP142) assay has proven to be highly sensitive for ICs and less sensitive for TCs [31],
whereas the DAKO 22C3 and 28-8 assays show similar sensitivity for PD-L1 expression on TCs and lower
sensitivity for PD-L1 staining on ICs [19]. Nevertheless, several studies have shown the benefit of using the
VENTANA PD-L1 (SP142) assay to identify which patients with mTNBC will more likely benefit from treatment
with atezolizumab [29,30,32].
According to the IMpassion130 trial, detection of PD-L1-positive ICs by VENTANA PD-L1 (SP142) predicted
PFS and OS benefits with atezolizumab plus nab-paclitaxel in mTNBC patients [15,29,30]. This trial assessed PD-
L1 expression on ICs using the VENTANA PD-L1 (SP142) immunohistochemistry assay with a ≥1% cut-off
for positivity. In the PD-L1-positive group, the PFS was 7.5 months in patients treated with atezolizumab plus
nab-paclitaxel and 5.0 months in patients treated with nab-paclitaxel (HR: 0.62; 95% CI: 0.49–0.78; p < 0.001).
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Similarly, OS was 25.4 months in PD-L1-positive patients treated with atezolizumab plus nab-paclitaxel and
17.9 months in patients receiving nab-paclitaxel (not formally tested due to the prespecified hierarchical statistical
plan) [15,29,30]. The study concluded that the combination of atezolizumab plus nab-paclitaxel provides a clinical
benefit, especially in the PD-L1-positive subgroup. Therefore, it is crucial to assess PD-L1 expression on ICs to
inform treatment choices for mTNBC patients [29,30].
As explained in detail above, PD-L1 expression can be evaluated using various immunohistochemistry assays. The
post-hoc analysis of IMpassion130 assessed analytical and clinical concordance for the DAKO 22C3, VENTANA
SP142 and VENTANA SP263 assays [32]. In this analysis, two algorithms were run to evaluate PD-L1. The
VENTANA SP142 and VENTANA SP263 assays followed a PD-L1 IC algorithm, defined as the presence of
discernible PD-L1 staining of any intensity in ICs covering ≥1% of tumor area occupied by TCs and associated
intratumoral and continuous peritumoral stroma. The DAKO 22C3, on the other hand, followed a CPS algorithm,
understood as the number of PD-L1-stained cells (TCs, lymphocytes and macrophages) divided by the total number
of viable TCs, multiplied by 100. According to the results of this study, the immunohistochemistry assays were
not interchangeable. The overall percentage agreement was 69% between VENTANA SP142 and SP263 and 64%
between VENTANA SP142 and DAKO 22C3 [32]. In addition, the results showed that the clinical benefit in the
subgroups that were positive for DAKO 22C3 (HR: 0.78; 95% CI: 0.62–0.99) and VENTANA SP263 (HR: 0.75;
95% CI: 0.59–0.96) was driven by the VENTANA SP142-positive subgroup (HR: 0.71; 95% CI: 0.52–0.98).
Apart from the benefit observed in terms of HR: SP142-positive subgroups also had the longest median values for
PFS (8.3 vs 3.9 months) and OS (27.3 vs 17.9 months) [32]. These results led to the VENTANA PD-L1 (SP142)
assay at an IC cut-off ≥1% becoming the approved diagnostic test for identification of mTNBC patients most
likely to benefit from the addition of atezolizumab to nab-paclitaxel.
Additionally, according to recent data from the KEYNOTE-355 trial, the combination of pembrolizumab and
several chemotherapy backbones produced a statistically significant and clinically meaningful improvement in PFS
in patients with previously untreated locally recurrent inoperable TNBC or mTNBC whose tumors expressed
PD-L1 (CPS ≥1 or 10%), as assessed using the 22C3 pharmDx assay. In the CPS ≥10% population, the median
PFS of the combination was 9.7 months, and the median PFS of chemotherapy alone was 5.6 months (HR: 0.65;
95% CI: 0.49–0.86) [17]. Nevertheless, no data for OS were presented after 25.9 months of follow-up. These results
might lead to the approval of pembrolizumab for PD-L1 (22C3)-selected mTNBC patients, since this drug is not
currently approved as first-line treatment in these patients.
Is interpretation based on SP142 reproducible?
Between March and September 2019, 83 pathologists from various hospitals in Spain participated in a TNBC
training program for the VENTANA PD-L1 (SP142) assay. Each session involved a theoretical and a practical
component. Pathologists were trained to identify the presence or absence of discernible PD-L1 staining of any
intensity in ICs covering a certain percentage of tumor area occupied by TCs and associated intratumoral and
adjacent peri-tumoral stroma and, eventually, assigned each case a binary score when <1% IC or ≥1% IC, as
described in the VENTANA PD-L1 (SP142) assay interpretation guide for TNBC [33]. Therefore, a proficiency
test on 28 digital whole scanned cases produced two results for each case and each participating pathologist: one
raw score (IC %) and one binary result: positive or negative. The result for each assessed case was compared with
a consensus score established by an expert panel with prior established experience in PD-L1 scoring. The inter-
observer concordance analysis revealed a Spearman rank correlation coefficient of 0.970 (p < 0.001), indicating
a good correlation between the participants’ observations and the consensus scores previously established by the
expert panel. Figure 1 shows all numerical observations made by the participants.
These results are similar to those reported elsewhere [23,34,35]. Several trials have assessed the inter-observer
reproducibility of the results of the VENTANA PD-1 (SP142) assay. Noske et al. performed the first multicenter
study based on staining of whole slides in TNBC with trained readers in a real-world setting to compare the
reproducibility and analytical concordance of PD-L1 IC positivity between four anti-PD-L1 assays: VENTANA
SP263, VENTANA SP142, DAKO 22C3 and DAKO 28-8 [22]. Importantly, inter-reader agreement on PD-L1
IC positivity was higher with VENTANA SP142 than VENTANA SP263, DAKO 22C3 and DAKO 28-8 [22].
This high inter-reader agreement was confirmed in another study, which reported the results of a global training
program for the VENTANA SP142 assay with respect to interpretation of PD-L1 expression in TNBC [34]. However,
assessment of interobserver concordance using other methods has not yielded the same results. Reisenbichler et al.
concluded that IC scoring with both the SP142 and the SP263 assays showed poor reproducibility across multiple
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Figure 1. Analysis of agreement between pathologists in the Spanish PD-L1 (SP142) triple-negative breast cancer training program. Box
plot by case ID for immune cell percentage. PD-L1 (SP142) assay triple-negative breast cancer mean proficiency trainee test scores
compared with expert consensus scores and case-level agreement. Scores for each case were averaged across a total of 83 pathologists
who attended the training program. The median for each dataset is indicated by the black center line, and the first and third quartiles
are the edges of the box area, which is known as the IQR. The extreme values (within 1.5-times the IQR from the upper or lower quartile)
are the ends of the lines extending from the IQR (circles). Points at a greater distance from the median than 1.5-times the IQR are plotted
individually as asterisks. These points represent potential outliers.
IC: Immune cell; IQR: Interquartile range.
pathologists using their Observers Needed to Evaluate Subjective Tests analysis. The authors suggest that an assay
similar to this one should be interpreted by at least eight to ten pathologists rather than two or three in order to
provide a true picture of the reproducibility of the assay in a real-world setting [35].
What is the recommended PD-L1 diagnostic algorithm? Should this biomarker be included in
parallel to HER2 & hormone receptor testing?
In general terms, it was concluded that PD-L1 should be determined in all mTNBC patients. Thus, once a negative
result has been confirmed for HER2, estrogen and progesterone receptors, thus leading to a diagnosis of TNBC,
PD-L1 should be performed in parallel. However, divergences emerged as to whether PD-L1 determination should
be done in the early stage of the disease or only when the tumor has metastasized. According to the clinical course
of TNBC, most patients presenting with metastases will experience recurrences from early stages (94%), whereas
those with de novo metastases will be a minority (6%) [36]. Therefore, PD-L1 could be assessed in early TNBC or
once the disease has metastasized. Some experts believed that considering the bad prognosis and the pressing unmet
needs of TNBC patients, it would be beneficial to perform the PD-L1 evaluation in early-stage TNBC so that the
PD-L1 status was known before the tumor metastasized. In contrast, other experts thought that considering that
not all early-stage TNBC recurs, PD-L1 should be assessed once the disease has metastasized in order to ensure
a sustainable use of clinical resources. Moreover, considering emerging data from clinical research in TNBC, the
therapeutic options would need to be further evaluated using biomarkers upon recurrence. Therefore, no consensus
was achieved on whether the evaluation should be performed in early-stage TNBC or mTNBC.
How does the frequency of PD-L1 differ depending on the sample evaluated? Should any tissue be
prioritized? How many tests are needed to define a patient’s PD-L1 status?
According to various studies, expression of PD-L1 differs significantly between primary and metastatic tumors and
is more frequent in primary tumors [37,38]. In their post-hoc analysis of IMpassion130 samples, Rugo et al. reported
that expression of PD-L1 in primary tissue was higher than in metastasis (44 vs 36%; p = 0.014). They also showed
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Figure 2. Proposed PD-L1 testing algorithm in metastatic triple-negative breast cancer.
that PD-L1 remains a predictor of response, regardless of the origin of the sample [32]. Therefore, primary tissue
should be prioritized when addressing PD-L1 expression in mTNBC patients. Nevertheless, not all primary tumors
are appropriate. Data on PD-L1 expression in residual invasive cancer after neoadjuvant chemotherapy are not
consistent. Some authors report lower PD-L1 values in the residual tumor than in the primary carcinoma [39,40],
although contrasting findings were recently published [41]. Given the scarcity of available data and the discrepancies
observed, the expert committee recommends avoiding these samples when analyzing PD-L1, unless no other sample
is available.
Few data have been reported on concordance of PD-L1 in matched specimens; however, available evidence
suggests that results may be discordant in a percentage of patients [37]. Therefore, if PD-L1 is evaluated only in the
primary tumor, PD-L1 status may be misclassified, since, according to the IMpassion130 trial design, if multiple
tumor specimens are submitted for enrollment, the PD-L1 score used to stratify the patient is the maximum
score. Taking into account the above-mentioned observations, the expert committee recommends evaluating the
expression of PD-L1 first in the primary tumor and, if the result is negative, at least in one metastasis. The proposed
workflow is shown in Figure 2.
Importantly, since mTNBC patients have a poor prognosis, therapy must be chosen as soon as possible. At this
meeting, the time that a TNBC patient can wait for a biomarker-based diagnosis was not discussed; therefore, it is
essential to consider this aspect in future consensus discussions.
Should an order of priority be established according to the origin of the metastatic tissue sample?
As stated previously and shown in Figure 2, the primary tumor is the priority sample for evaluation of PD-L1;
metastases should only be tested if the primary tumor is negative or not suitable.
Expression of PD-L1 differs according to anatomical location; expression of PD-L1 in ICs is more frequent in
lymph nodes (51%), followed by skin (48%), lungs (43%), breast (43%) and other locations (36%) [32]. Yuan et al.
reported significant differences in expression of PD-L1 between primary breast tumors and paired axillary lymph
nodes. The positive rate of PD-L1 expression in primary tumors and matched lymph nodes was 29.8 and 14.8%,
respectively (p = 0.016) [42]. These authors also observed that positivity of PD-L1 in metastatic lymph nodes was
significantly associated with poor prognostic features, such as high Ki-67 index, high TNM stage, high histology
grade and large number of metastatic lymph nodes [42].
Taking the above into account, priority should be given according to positivity; consequently, lymph nodes are
the sample of choice for evaluation of PD-L1 in metastases.
When assessing the expression of PD-L1 in metastatic samples, should we take any specific aspects
into account (e.g., are there any samples we should avoid)?
Bone samples are not recommended for assessing the expression of PD-L1, as aggressive decalcification treatment
decreases the antigenicity of the samples [43]. In addition, assessment of PD-L1 in liver metastases should be avoided,
given that this sample type is rarely associated with tumor infiltrating lymphocytes or an immunosuppressive
environment [44]. However, there are no published data advising against these samples, since they may be the only
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available metastatic samples, and any positive sample is sufficient to identify atezolizumab-eligible patients. Thus,
the recommendation is that these samples should not be prioritized or be the first to be tested.
Furthermore, lymph node metastases are complex to evaluate for various reasons. First, the VENTANA PD-L1
(SP142) assay considers only ICs [45]. Second, lymph nodes are rich in ICs. Third, it is difficult to delimit the
tumor area and tumor stroma in lymphoid tissue. Therefore, the expert panel consulted here concluded that, given
the high frequency of PD-L1 positivity and the distinctiveness of lymph node metastases, special care is required
with this sample. In cases of doubt, an expert should be consulted.
Given the current immunotherapy landscape & the large number of ongoing clinical trials, is it
useful to specify the antibody clone used for assessment of PD-L1 status in the pathology report?
Because several approved immunotherapy options target the PD-L1/PD-1 axis in various types of cancer, it is
always necessary to specify the antibody clone used in the assessment of this biomarker in the pathology report. As
previously mentioned, each antibody clone has been validated concomitantly with the clinical development of anti-
PD-1/PD-L1 therapy [18,19,23]. Therefore, in the report for TNBC, it is necessary to specify not only the PD-L1
antibody clone assayed (22C3, 28-8, SP142, SP263 and 73-10), but also the platform used for its detection (DAKO
Autostainer Link 48 platform or VENTANA BenchMark Ultra platform). In addition, guidelines recommend that
both the qualitative value of the expression (positive vs negative) and the quantitative value (percentage of positive
TCs and percentage of positive ICs) be specified [46]. This approach is important when deciding on the best
treatment from among newly introduced therapeutic agents in clinical practice. Furthermore, and especially in the
case of the SP142 clone, it is strongly recommended to report the proportion of the tumor area occupied by ICs [47].
Future perspective
Immunotherapy is increasingly used in many tumors because of the significant clinical advantages it provides.
However, not all patients benefit from it. To select the best candidates for immunotherapy, it is necessary to search
for and identify biomarkers with a strong predictive value that are expressed by specific patient populations. This
has proved to be the case for PD-L1 in mTNBC. Detection of PD-L1 in these tumors makes it possible to prescribe
anti-PD-L1 treatment such as atezolizumab and thus achieve an optimal response.
However, in addition to enabling detection of this biomarker, the procedure (i.e., immunohistochemistry staining
followed by scoring) needs to be effective and reproducible to guarantee that the selected therapy is appropriate
for the individual patient. Although many advances have been made in this regard, further concordance studies,
protocols, and guidelines are still needed to help physicians determine which samples to use, at which stage of the
disease to test and, in summary, how to detect PD-L1 more consistently for the benefit of the patient.
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Executive summary
Introduction
• Triple-negative breast cancer (TNBC) tends to be more aggressive than other breast cancer subtypes.
• TNBC has proven to be more immunogenic than other breast cancer subtypes, with higher expression of PD-L1.
• PD-1/PD-L1 has emerged as a promising therapeutic target in breast cancer subtypes.
• PD-L1 expression is a positive predictive factor of response.
• It is important to assess the level of expression of PD-L1 in TNBC in order to select patients who may benefit from
available therapies.
Methods for assessing PD-L1 expression
• There are several PD-L1 assays for use with each anti-PD-L1 drug.
• The immunohistochemistry assay includes an antibody clone (22C3, 28-8, SP142, SP263 and 73-10) to be used with
a specific detection platform (DAKO Autostainer Link 48 platform, Agilent Inc and VENTANA BenchMark Ultra
platform, Ventana Medical Systems Inc.).
• The sensitivity of the detection kit for detecting PD-L1 varies depending on whether the test is performed on
tumor cells (TCs) or immune cells (ICs).
• The SP142 kit stains more ICs but fewer TCs than kits based on the other PD-L1 antibodies. Conversely, the 22C3
and 28-8 antibodies show robust sensitivity with TCs, but less pronounced staining of ICs.
• The only PD-L1 assay licensed as a companion diagnostic device for selecting TNBC patients who are candidates
for atezolizumab plus nab-paclitaxel is the VENTANA platform using the SP142 antibody clone.
Discussion
• The VENTANA PD-L1 (SP142) assay has proven to be highly sensitive for PD-L1 expression on ICs, but less sensitive
for PD-L1 detection on TCs. However, scientific evidence has shown that this detection system identified patients
treated with atezolizumab plus nab-paclitaxel with longer median progression-free survival and overall survival
than the other platforms.
• Inter-reader agreement on PD-L1 IC positivity (0.805) was higher with the VENTANA PD-L1 (SP142) assay than
with the VENTANA SP263 (0.616), DAKO 22C3 (0.605) and DAKO 28-8 (0.460) assays.
• According to the VENTANA PD-L1 (SP142) assay, the expression of PD-L1 in ICs is significantly higher in primary
tumors than in metastatic tumors; in addition, expression is highest in the lymph nodes.
• Liver and bone samples should not be the first samples evaluated to assess PD-L1 expression.
• Expression of PD-L1 in lymph node metastases is more difficult to assess with the VENTANA PD-L1 (SP142) assay
because this detection system considers only ICs, lymph nodes contain abundant ICs and it is difficult to delimit
the tumor area in lymphoid tissue.
• PD-L1 status should be routinely assessed in the primary tumor, and, if the result is negative, the evaluation
should be made in a recent metastatic sample.
• The pathology report for TNBC must include the antibody clone and the platform used for detection of PD-L1, as
well as qualitative and quantitative expression data.
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